RxDoctor Payments Data

Juan Sam, MD

Internal Medicine · Los Angeles, CANPI 1033278031

Payments from drug & device makers

$980in general payments, 2019–2025

Across 27 payments — averaging $36.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$364
  • Amarin Pharma, Inc.$193
  • Bayer$164
  • Cardiovascular Systems Inc.$54
  • Amgen$48
  • Pfizer$47
  • plus $110 from 4 others

What the payments were for

  • Food & beverage$97499%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$980 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$28,327
Medicare patients
94
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate201$172,827
JardianceEmpagliflozin89$104,289
RybelsusSemaglutide52$95,958
VascepaIcosapent Ethyl95$56,350
Icosapent Ethyl109$42,203
TradjentaLinagliptin39$41,259
Metformin Er GastricMetformin Hcl15$28,288
EliquisApixaban29$26,792
Omega-3 Acid Ethyl Esters282$22,260
FarxigaDapagliflozin Propanediol15$18,647
EntrestoSacubitril/Valsartan14$14,657
Ezetimibe321$11,165
TrulicityDulaglutide12$11,103
NeuproRotigotine11$9,326
Olmesartan Medoxomil330$8,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$364$95,95852 claims
PfizerEliquis$47$26,79229 claims
NovartisEntresto$42$14,65714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →